Developing a new vaccine approach to help achieve a functional cure for HIV
Exploiting Highly Networked CTL Epitopes to Achieve a Functional HIV Cure
This study is exploring a new way to help people with HIV by developing a vaccine that boosts the immune system to fight the virus more effectively, which could mean less reliance on lifelong medication and possibly even a functional cure.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10909082 on NIH RePORTER |
What this research studies
This research investigates a novel approach to combat HIV by focusing on highly networked cytotoxic T cell (CTL) epitopes that are resistant to mutation. The goal is to create a therapeutic vaccine that can effectively stimulate the immune system to target these specific epitopes, potentially reducing the need for lifelong antiretroviral therapy. By utilizing advanced network analysis of HIV protein structures, the study aims to identify and leverage CTL responses that can prevent the virus from rebounding after treatment cessation. Patients may benefit from this innovative strategy if it leads to a functional cure for HIV.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who are currently on combination antiretroviral therapy and are interested in potential new treatment options.
Not a fit: Patients who are not infected with HIV or those who have advanced AIDS may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a functional cure for HIV, significantly improving the quality of life for those living with the virus.
How similar studies have performed: While there have been various approaches to HIV treatment, this specific focus on highly networked CTL epitopes represents a novel and untested strategy.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Gaiha, Gaurav Das — Massachusetts General Hospital
- Study coordinator: Gaiha, Gaurav Das
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.